{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:45:43Z","timestamp":1762004743911},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,27]],"date-time":"2016-02-27T00:00:00Z","timestamp":1456531200000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BioMarin Pharmaceutical, Inc., Novato, CA"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ymgme.2015.10.006","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T00:20:18Z","timestamp":1445732418000},"page":"157-163","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations"],"prefix":"10.1016","volume":"117","author":[{"given":"Therese","family":"Ruane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Haskins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alphonsus","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"IV","given":"Van W. (Rafe)","family":"Knox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2015.10.006_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","article-title":"Mucopolysaccharidosis VI","volume":"5","author":"Valayannopoulos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0010","series-title":"Naglazyme\u00ae (galsulfase) solution for intravenous infusion only, [prescribing information","year":"2005"},{"key":"10.1016\/j.ymgme.2015.10.006_bb0015","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1172\/JCI118617","article-title":"Enzyme replacement therapy in a feline model of Maroteaux\u2013Lamy syndrome","volume":"97","author":"Crawley","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/08035320510028139","article-title":"Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux\u2013Lamy syndrome): a phase I\/II study","volume":"94","author":"Harmatz","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0025","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2015.10.006_bb0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10545-013-9654-7","article-title":"Galsulfase (Naglazyme\u00ae) therapy in infants with mucopolysaccharidosis VI","volume":"37","author":"Harmatz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0040","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1542\/peds.2007-0665","article-title":"Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme])","volume":"121","author":"Kim","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2015.10.006_bb0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10545-008-0980-0","article-title":"Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively","volume":"31","author":"Bagewadi","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0050","first-page":"657","article-title":"The pathology of the feline model of mucopolysaccharidosis VI","volume":"101","author":"Haskins","year":"1980","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-008-0821-1","article-title":"Clinical characterization of cardiovascular abnormalities associated with feline mucopolysaccharidosis I and VI","volume":"31","author":"Sleeper","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S8756-3282(97)00175-0","article-title":"Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI","volume":"21","author":"Byers","year":"1997","journal-title":"Bone"},{"key":"10.1016\/j.ymgme.2015.10.006_bb0065","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1203\/01.pdr.0000203090.41012.a6","article-title":"Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval","volume":"59","author":"Auclair","year":"2006","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0070","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ymgme.2007.04.009","article-title":"Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI","volume":"91","author":"Auclair","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/pr.2011.13","article-title":"Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats","volume":"71","author":"Auclair","year":"2012","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/PRM-2010-0115","article-title":"Radiologic and neuroradiologic findings in the mucopolysaccharidoses","volume":"3","author":"Lachman","year":"2010","journal-title":"J. Pediatr. Rehabil. Med."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2009.10.002","article-title":"Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen","volume":"99","author":"Auclair","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0090","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0003-2697(81)90795-8","article-title":"Differential assay of arylsulfatase A and B activities: a sensitive method for cultured human cells","volume":"117","author":"Chang","year":"1981","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/geno.1999.5825","article-title":"Molecular basis of feline beta-glucuronidase deficiency: an animal model of mucopolysaccharidosis VII","volume":"58","author":"Fyfe","year":"1999","journal-title":"Genomics"},{"key":"10.1016\/j.ymgme.2015.10.006_bb0100","series-title":"Clinical Chemistry","author":"Taylor","year":"1989"},{"key":"10.1016\/j.ymgme.2015.10.006_bb0105","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","article-title":"Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment","volume":"33","author":"Giugliani","year":"2010","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0110","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1542\/peds.2006-2184","article-title":"Management guidelines for mucopolysaccharidosis VI","volume":"120","author":"Giugliani","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2015.10.006_bb0115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/bmme.1996.0044","article-title":"Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I","volume":"58","author":"Kakkis","year":"1996","journal-title":"Biochem. Mol. Med."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0125","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"44","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1203\/01.PDR.0000113789.30640.5C","article-title":"Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry","volume":"55","author":"Crawley","year":"2004","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2015.10.006_bb0135","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1203\/00006450-200006000-00010","article-title":"Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency","volume":"47","author":"Byers","year":"2000","journal-title":"Pediatr. Res."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T06:23:33Z","timestamp":1599719013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719215300640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1096719215300640"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.10.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}